About: Hydroxychloroquine treatment in COVID‐19: a descriptive observational analysis of 30 cases from a single center in Wuhan, China

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Hydroxychloroquine treatment in COVID‐19: a descriptive observational analysis of 30 cases from a single center in Wuhan, China Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Hydroxychloroquine treatment in COVID‐19: a descriptive observational analysis of 30 cases from a single center in Wuhan, China
Creator	Liu, Yi Li, Juan Liu, Dong Luo, Pan Liu, Xiulan Qiu, Lin Xue, Huiying
source	Medline; PMC
abstract	Hydroxychloroquine (HCQ) garnered scientific attention in early February following publication of reports showing in vitro activity of chloroquine (CQ) against COVID‐19. While studies are mixed on this topic, the therapeutic effect of HCQ or CQ still need more valid clinical evidence. In this descriptive observational study, we aimed to discuss the treatment response of HCQ in COVID‐19 infected patients and 30 cases were included. The demographic, treatment, laboratory parameters of C‐reactive protein (CRP) and interleukin‐6 (IL‐6) before and after HCQ therapy and clinical outcome in the 30 COVID‐19 patients were assessed. In order to evaluate the effect of mediation time point, we also divided these cases into two groups, patients began administrated with HCQ within 7 days hospital (defined as early delivery group) and 7 days after hospital (defined as later delivery group). We found that, the elevated IL‐6, a risk factor in severe patients were reduced to normal level after HCQ treatment. More importantly, patients treated with HCQ at the time of early hospital recovered faster than those who treated later or taken as second line choose for their obvious shorter hospitalization time. In summary, early use of HCQ was better than later use and the effect of IL‐6 and CRP level can not be ruled out. This article is protected by copyright. All rights reserved.
has issue date	2020-06-17(xsd:dateTime)
bibo:doi	10.1002/jmv.26193
bibo:pmid	32779755
has license	no-cc
sha1sum (hex)	173a9aa75e6999239d80524ebeb00e340404585e
schema:url	https://doi.org/10.1002/jmv.26193
resource representing a document's title	Hydroxychloroquine treatment in COVID‐19: a descriptive observational analysis of 30 cases from a single center in Wuhan, China
has PubMed Central identifier	PMC7323248
has PubMed identifier	32779755
schema:publication	J Med Virol
resource representing a document's body	covid:173a9aa75e6999239d80524ebeb00e340404585e#body_text
is schema:about of	named entity 'IL-6' named entity 'chloroquine' named entity 'administrated' named entity 'cases' named entity 'cases' named entity 'ATTENTION' named entity 'OBVIOUS' named entity 'CLINICAL' named entity 'ELEVATED' named entity 'PROTEIN ' named entity 'TREATMENT' named entity 'TREATED' named entity 'INFECTED' named entity '7 days' named entity 'clinical evidence' named entity 'time point' named entity 'order' named entity '7 days' named entity 'divided' named entity 'level' named entity 'hospital' named entity 'therapy' named entity 'recovered' named entity 'CRP' named entity 'COVID-19' named entity 'Running' named entity 'Hydroxychloroquine' named entity 'CRP' named entity 'COVID' named entity 'interleukin-6' named entity 'HCQ' named entity 'HCQ' named entity 'IL-6' named entity 'HCQ' named entity 'IL-6' named entity 'COVID-19' named entity 'wuhan' named entity 'single center' named entity 'critically ill' named entity 'early delivery' named entity 'cytokine storm' named entity 'cough' named entity 'mechanical ventilation' named entity 'HCQ' named entity 'preliminary research' named entity 'liver' named entity 'pharmacological treatment' named entity 'early delivery' named entity 'treatment group' named entity 'symptom' named entity 'inflammatory factors' named entity 'dyspnea' named entity '8.5' named entity 'diarrhea' named entity 'antiviral drugs' named entity 'HCQ' named entity 'autoimmune diseases' named entity 'COVID' named entity 'HCQ' named entity 'fatigue' named entity 'significant difference' named entity 'fatality rate' named entity 'COVID' named entity 'HCQ' named entity 'HCQ' named entity '80 years' named entity 'early delivery' named entity 'MERS-CoV' named entity 'WHO' named entity 'HCQ' named entity 'early delivery' named entity 'symptom' named entity 'critical illness' named entity 'inflammatory marker' named entity 'basic research'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software